Investor Presentaiton

Robust Pipeline Across Novel Therapeutics - Oncology 4 commercialized, 1 in NDA, 4 in pivotal trials and 11 assets in clinical stage Status Products Target (s) Modality Therapeutic Area Commercial Rights Pre-clinical IND Approved Phase 1 Phase 2 Pivotal Phase 2/ Phase 3 NDA Launched Lilly TYVYTⓇ (sintilimab injection) PD-1 Monoclonal antibody Oncology Worldwide BYVASDAⓇ (bevacizumab injection) VEGF-A Monoclonal antibody Oncology Lilly HALPRYZA® (rituximab injection) CD20 Monoclonal antibody Oncology Worldwide Worldwide Incyte) IBI-375 (Pemigatinib) FGFR1/2/3 Small molecule Oncology Mainland China, HK, Taiwan, Macau 2L MCCA (Approved in Taiwan, NDA accepted in mainland China and HK); 1L CCA (joined Incyte's global Phase 3 trial) Drug-resistant chronic myeloid leukemia (CML), NDA accepted in China IBI-348 (Olverembatinib) BCR-ABL/KIT Small molecule Oncology Mainland China, HK, Taiwan, Macau GIST Ph + ALL IBI-310 CTLA-4 Monoclonal antibody Oncology Worldwide Incyte IBI-376 (Parsaclisib) РІЗКО Small molecule Oncology Mainland China, HK, Taiwan, Macau IBI-326 BCMA CAR-T Cell therapy Oncology Worldwide AnHeart Therapeutics IBI-344 (Taletrectinib) ROS1/NTRK Small molecule Oncology Mainland China, HK, Taiwan, Macau Adjuvant melanoma 2L Cervical cancer 11 HCC Lr/r FL and MZL (China). Myelofibrosis (Incyte's global Phase 3) r/r multiple myeloma ↑ ROS1+ NSCLC (1L+2L). NTRK+ Solid tumors MDS (China) MDS (US) r/r AML (China) Phase 1b and Phase 2 for multiple cancer types in plan Advanced malignancies (China) Advanced malignancies (US Phase 1b for multiple cancer types IBI-188 CD47 Monoclonal antibody Oncology Worldwide IBI-110 LAG-3 Monoclonal antibody Oncology Worldwide IBI-322 PD-L1/CD47 Bispecific antibody Oncology Worldwide Lilly IBI-318 PD-1/PD-L1 Bispecific antibody Oncology Mainland China, HK, Macau Hanmi IBI-315 PD-1/HER2 Bispecific antibody Oncology Worldwide IBI-939 TIGIT Monoclonal antibody Oncology Worldwide IND approved (US) Lilly IBI-321 PD-1/TIGIT Bispecific antibody Oncology Mainland China, HK, Macau Lilly IBI-319 PD-1/4-1BB Bispecific antibody Oncology Mainland China, HK, Macau IBI-323 LAG-3/PD-L1 Bispecific antibody Oncology Worldwide IBI-102 GITR Monoclonal antibody Oncology IBI-101 OX40 Monoclonal antibody Oncology Worldwide Worldwide Listed drugs Biologics Small molecules Clinical progress in the U.S. Robust oncology pipeline with 20 clinical stage assets, covering monoclonal antibodies, bispecific antibodies, CAR-T and small Innovent molecules Confidential Copyright©2021 Innovent Biologics 15

View entire presentation